moderate-to-severe atopic dermatitis
Galderma’s Nemluvio shows sustained improvements in moderate-to-severe atopic dermatitis
Up to 91% of patients achieved at least 75% improvement in eczema severity and up to 67% achieved near-complete skin clearance
Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood
Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms
Some patients found the treatment reduced itch and sleep disturbance within just two days
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis
The phase 3 study included around 2,600 patients
Galderma shares positive long-term data for Nemluvio in prurigo nodularis
The chronic skin disorder is estimated to affect up to 181,000 people in the US
Galderma shares positive two-year results for Nemluvio in atopic dermatitis
The chronic inflammatory skin disease affects more than 230 million people worldwide
MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases
EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha
CHMP recommends Galderma’s nemolizumab for atopic dermatitis and prurigo nodularis
The drug has been recommended for use in patients with moderate-to-severe cases of the skin diseases
Galderma announces positive late-stage results for nemolizumab in prurigo nodularis
The chronic skin condition is estimated to affect up to 181,000 people in the US
FDA approves Galderma’s IL-31 inhibitor Nemluvio to treat prurigo nodularis in adults
The chronic skin condition is estimated to affect up to 181,000 people in the US
Galderma’s nemolizumab shows promise in phase 3 prurigo nodularis trial
The condition affects more than 70 out of every 100,000 adults aged 18 to 64 years in the US